Breast Cancer

About Conference

The 7^th World Congress on Breast Cancer, scheduled to be held on May 05-06, 2027, in the historic and vibrant city of Berlin, Germany, is an internationally acclaimed scientific gathering designed to unite clinicians, researchers, oncologists, surgeons, pathologists, radiologists, pharmaceutical representatives, policy makers, patient advocates, and students from around the world. With a primary focus on innovation, education, and collaboration, this two-day congress is a significant platform dedicated entirely to exploring the most recent advancements, breakthroughs, and challenges in breast cancer research, diagnosis, treatment, and patient care. The 7^th edition of this esteemed conference comes at a critical time when global breast cancer incidence continues to rise, making it the most common cancer in women worldwide. According to WHO reports, one in eight women is likely to be diagnosed with breast cancer in her lifetime. Despite increased awareness and progress in early detection and therapy, there are persisting disparities in outcomes due to late diagnosis, limited access to care in low-resource settings, and aggressive subtypes of the disease such as triple-negative breast cancer. 

The conference will encompass a wide array of scientific sessions and keynote addresses delivered by world-renowned experts. The scientific program is designed to cover basic and translational research, clinical trials, surgical and radiation oncology, immunotherapy, targeted therapy, genetics and genomics, liquid biopsies, AI and digital imaging, molecular biology, nursing and patient-centered care, and survivorship issues. Special sessions will be dedicated to HER2-positive and triple-negative breast cancer, metastatic disease, male breast cancer, young women with breast cancer, and breast cancer in low- and middle-income countries. Attendees will gain valuable insights into how personalized medicine and multi-omics approaches are transforming the breast cancer care landscape. A highlight of the congress is the focus on innovative diagnostics and early detection strategies, including artificial intelligence (AI)-driven imaging, liquid biopsies, and risk prediction models, which are revolutionizing how breast cancer is diagnosed at earlier, more treatable stages. 

The selection of Berlin, Germany, as the host city offers a unique blend of historical richness, cultural diversity, and scientific excellence. Berlin's legacy of intellectual exploration and its modern infrastructure make it a perfect venue for this prestigious gathering. Delegates will have the chance to experience a scientifically rewarding program while enjoying the charm of the Eternal City—from the Berlin TV Towe, Berlin Cathedral and Brandenburg Gate. The Breast Cancer 2027 is more than just a conference—it is a movement toward a future where breast cancer is no longer a life-threatening disease.

Sessions & Tracks

Track–1: Immunotherapy in Breast Cancer

Immunotherapy has emerged as one of the most transformative approaches in oncology, and its application in breast cancer is opening new avenues for patient care, especially in aggressive and treatment-resistant subtypes. This session will explore the evolving role of immunotherapeutic strategies in breast cancer, including checkpoint inhibitors, cancer vaccines, and adoptive cell therapies. Unlike more immunogenic tumors such as melanoma or non-small cell lung cancer, breast cancer has traditionally been considered immunologically "cold." However, recent studies have shown that certain subtypes, particularly triple-negative breast cancer (TNBC), may respond favorably to immunotherapeutic agents when combined with conventional therapies like chemotherapy. This session will highlight the mechanisms by which breast tumors evade immune surveillance and how new treatments are being designed to counteract these processes. Clinical trial data will be presented to assess the efficacy and safety of these agents in both early-stage and metastatic breast cancer settings.

Track–2: Breast Cancer Survivorship and Quality of Life

As breast cancer survival rates continue to improve due to advances in treatment and multidisciplinary care, a new frontier of care has emerged—long-term survivorship. Breast cancer survivorship is not a singular phase but a dynamic continuum that spans years, often decades, after initial diagnosis and therapy. With survival comes the reality of persistent or late-emerging effects of treatment. The psychosocial aspect of survivorship is another major theme. Many breast cancer survivors experience anxiety, depression, fear of recurrence, and challenges related to body image, sexuality, and identity returning to work, rebuilding relationships, and managing the expectations of others can create stress and uncertainty. Presenters will discuss strategies to support patients through these transitions, particularly for women who are caregivers themselves or who face cultural stigmas around cancer survivorship. 

Track–3: Triple-Negative Breast Cancer Research

Triple-Negative Breast Cancer (TNBC) represents one of the most aggressive and clinically challenging subtypes of breast cancer, accounting for approximately 15–20% of all breast cancer diagnoses. Characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and HER2 amplification, TNBC does not respond to most endocrine or HER2-targeted therapies, leaving chemotherapy and newer systemic treatments as the main therapeutic approaches. TNBC is highly diverse at the molecular level. Researchers will present updates on intrinsic subtypes such as basal-like, mesenchymal, and luminal androgen receptor (LAR), each with distinct genetic and signaling features. Understanding these subtypes has major implications for prognosis and targeted treatment. 

Track–4: Immunotherapy and Breast Cancer

Immunotherapy is revolutionizing the landscape of cancer treatment, and its application in breast cancer is rapidly evolving. Although traditionally considered less immunogenic than other tumor types, certain subtypes of breast cancer—most notably triple-negative breast cancer (TNBC)—have shown responsiveness to immune-based therapies. Combination strategies represent a major focus in current research. The synergy between immunotherapy and chemotherapy, targeted therapy, and radiation is under intense investigation. Experts will share insights from recent trials exploring these combinations, aiming to enhance immune system activation while overcoming resistance mechanisms. Checkpoint blockade has emerged as the most promising immunotherapy strategy in breast cancer. Inhibitors targeting programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and CTLA-4 are being actively studied and utilized. 

Track–5: HER2-Positive Breast Cancer Advances

HER2-positive breast cancer, defined by the overexpression or amplification of the human epidermal growth factor receptor 2 (HER2), accounts for approximately 15–20% of all breast cancer cases. Once associated with a poor prognosis, HER2-positive breast cancer has become one of the most treatable subtypes due to the development of highly effective targeted therapies. By understanding the molecular underpinnings of HER2-positive disease, participants will gain insight into why this subtype responds so well to targeted therapies. HER2-directed therapies that have transformed patient outcomes. Landmark agents such as trastuzumab and pertuzumab remain the backbone of treatment, especially in early and metastatic settings. Presenters will discuss optimal combinations, duration of therapy, and updates from pivotal trials like CLEOPATRA, APHINITY, and KATHERINE.

Track–6: Hormone Receptor-Positive Subtypes

Hormone receptor-positive (HR+) breast cancers represent the most prevalent subtype, accounting for approximately 70% of all breast cancer diagnoses. These tumors express estrogen receptors (ER), progesterone receptors (PR), or both, and are typically characterized by slower growth and a more favorable prognosis compared to other subtypes. However, despite the initial responsiveness to endocrine therapies, recurrence and treatment resistance remain significant challenges. These insights form the basis for tailoring treatment approaches and predicting outcomes.The main focus will be on endocrine therapy, which remains the cornerstone of treatment for HR+ breast cancer. Speakers will examine the use of selective estrogen receptor modulators (SERMs) such as tamoxifen, aromatase inhibitors (AIs), and selective estrogen receptor degraders (SERDs), highlighting indications, efficacy, and adverse effect profiles. 

Track–7: Breast Cancer Biomarkers and Prognosis

The identification and application of biomarkers have revolutionized the diagnosis, treatment planning, and prognosis of breast cancer. Breast cancer is a highly heterogeneous disease with varying clinical behaviors and treatment responses. Biomarkers serve as measurable indicators of the biological state of a tumor and can be used to classify breast cancer into subtypes, assess aggressiveness, forecast likely clinical outcomes, and predict responsiveness to specific therapies. Beyond these classical markers, attention will turn to proliferation markers such as Ki-67, which provide insights into tumor growth rate and have implications for treatment intensity. Experts will discuss the challenges and variability in Ki-67 assessment, and its evolving utility in distinguishing luminal A from luminal B tumors, and its role in neoadjuvant settings. These tests analyze the expression of multiple genes within a tumor to provide prognostic scores and treatment recommendations. 

Track–8: Radiation Oncology in Breast Cancer

Radiation oncology plays a pivotal role in the multidisciplinary treatment of breast cancer, significantly improving local control and overall survival across various stages of the disease. Hypofractionated whole-breast irradiation (WBI) has been validated through major trials (such as START and FAST-Forward) to be equally effective and safe as conventional fractionation, with added convenience for patients. The session will compare standard and hypofractionated regimens, highlighting patient selection, toxicity profiles, and long-term cosmetic outcomes. The advantages, limitations, and patient eligibility criteria for PBI using techniques such as brachytherapy, external beam radiation, and intraoperative RT will be examined.For locally advanced breast cancer, post-mastectomy radiation therapy (PMRT) remains a critical component of treatment. 

Track–9: Surgical Innovations in Breast Cancer

Surgery remains a foundational component in the treatment of breast cancer, offering both curative and palliative options. Over the past few decades, significant innovations in surgical techniques have reshaped the landscape of breast cancer care—shifting from radical approaches to more precise, personalized, and aesthetically mindful procedures. Tools such as intraoperative ultrasound, cavity-shave margins, and emerging margin assessment technologies (like optical spectroscopy and micro-CT) will be reviewed for their impact on re-excision rates and local recurrence. 

Track–10: Neoadjuvant and Adjuvant Therapies

Neoadjuvant and adjuvant therapies have become essential pillars in the comprehensive treatment of breast cancer, significantly improving survival rates and enabling tailored, stage-appropriate care. Neoadjuvant therapy, which involves administering systemic treatments prior to surgery, has gained prominence, especially in patients with triple-negative, HER2-positive, or locally advanced disease. Its primary goals are to reduce tumor size, increase the likelihood of breast-conserving surgery, assess treatment response in vivo, and provide early systemic control. Adjuvant therapy, given after primary surgery, remains a cornerstone in early-stage breast cancer management. 

Track–11: Targeted Therapy and Drug Development

Targeted therapy has transformed the landscape of breast cancer treatment by shifting the focus from non-specific cytotoxic agents to precise, molecularly directed interventions. Unlike traditional chemotherapy, targeted therapies are designed to interfere with specific molecular pathways that drive tumor growth and survival. This session will begin by exploring the key molecular targets in breast cancer—such as HER2, CDK4/6, PI3K, and PARP—and the mechanisms through which these targets are manipulated to achieve therapeutic benefit. The success of HER2-directed therapies (trastuzumab, pertuzumab, T-DM1) in altering the course of HER2-positive breast cancer will be discussed as a foundational model of targeted treatment. Clinical trial data supporting their use in both metastatic and early-stage disease will be presented, along with discussions on resistance mechanisms, adverse effect profiles, and ongoing trials aimed at overcoming therapeutic limitations. 

Track–12: Breast Cancer in Men

Though often perceived as a disease affecting only women, breast cancer in men is a rare but important clinical entity that demands greater attention in both research and practice. Accounting for less than 1% of all breast cancer cases, male breast cancer (MBC) presents unique biological, diagnostic, psychological, and therapeutic challenges that distinguish it from its female counterpart. While genetic mutations such as BRCA2 play a significant role, other contributors—including advancing age, radiation exposure, liver disease, estrogen-related conditions (e.g., Klinefelter syndrome), and family history—will be reviewed. Particular emphasis will be placed on the role of hereditary factors and the need for genetic counseling and testing in male patients, especially in the context of familial cancer syndromes. A major challenge in MBC is delayed diagnosis, often due to low public and clinical awareness, as well as social stigma. Unlike women, men are not routinely screened for breast cancer, leading many to present with more advanced disease. 

Track–13: Young Women and Breast Cancer

Health equity and access will be addressed by examining disparities in outcomes across socioeconomic, racial, and geographic lines. Strategies to improve trial enrollment, outreach, and access to novel therapies for underserved populations will be emphasized. Health equity and access will be addressed by examining disparities in outcomes across socioeconomic, racial, and geographic lines. Strategies to improve trial enrollment, outreach, and access to novel therapies for underserved populations will be emphasized. From a biological standpoint, breast cancer in younger women is more likely to present as triple-negative or HER2-positive subtypes, which are typically more aggressive and associated with poorer prognosis. This session will highlight the molecular and clinical characteristics that differentiate tumors in young women from those in older patients, informing decisions about personalized treatment planning. 

Track–14: Metastatic Breast Cancer Management

As breast cancer progresses to more advanced stages, its complexity increases significantly, demanding a multidisciplinary, patient-centered approach. Molecular profiling and liquid biopsy are increasingly essential in guiding individualized treatment decisions. These tools allow clinicians to identify actionable mutations and resistance patterns, enabling tailored therapies that align with tumor biology and patient needs. Central to the discussion will be novel therapeutic agents and combination strategies, including CDK4/6 inhibitors, PI3K inhibitors, PARP inhibitors, and antibody-drug conjugates. These treatments have significantly transformed the standard of care for hormone receptor-positive and HER2-positive disease, extending progression-free and overall survival in many patients. In parallel, immunotherapy and targeted treatments are becoming promising options for selected patient subsets, particularly those with triple-negative subtypes. 

Track–15: Breast Cancer Prevention Strategies

Prevention remains one of the most powerful tools in reducing the global burden of breast cancer. As the incidence of breast cancer continues to rise across both developed and developing nations, the implementation of effective, evidence-based prevention strategies has become a global priority. These include lifestyle elements such as diet, physical activity, alcohol consumption, obesity, reproductive choices, and exposure to environmental carcinogens. Scientific evidence has consistently shown that regular physical activity, a healthy weight, and reduced alcohol intake can significantly lower breast cancer risk. Genetic counseling and risk-reducing strategies are also key components of personalized prevention. Individuals with a strong family history or known mutations in genes like BRCA1, BRCA2, TP53, or PALB2 may benefit from tailored risk-reducing options. 

Market Analysis

The global landscape of breast cancer has undergone significant transformation between 2020 and 2030, influenced by shifting demographics, technological innovations, increasing healthcare investments, and rising awareness. Breast cancer remains the most frequently diagnosed cancer among women globally, contributing to approximately 2.3 million new cases in 2020 alone, and the burden is projected to rise steadily through 2030. The evolution of diagnostics, therapeutics, and public health policies has driven substantial changes in both the clinical and commercial domains of breast cancer care. Between 2020 and 2030, breast cancer incidence is expected to rise by 25–30%, primarily due to aging populations, sedentary lifestyles, increasing obesity rates, alcohol consumption, and reproductive health changes.

Regions like Asia-Pacific, Latin America, and parts of Africa are seeing rapid increases in breast cancer cases, fueled by urbanization and lifestyle changes. In contrast, developed regions such as North America and Western Europe are witnessing stable or slightly increasing incidence but with improved survival rates due to early detection and access to advanced therapies.The global breast cancer therapeutics market was valued at approximately USD 20 billion in 2020 and is projected to reach over USD 45 billion by 2030, registering a CAGR of 8–10%.North America continues to dominate the market owing to robust healthcare systems, strong reimbursement policies, and a high prevalence of breast cancer. However, Asia-Pacific is emerging as the fastest-growing market due to rising health expenditure, improving diagnostic access, and large patient populations in countries like China and India. Looking ahead, the global focus is shifting toward personalized, patient-centric, and value-based breast cancer care. Innovations such as genome editing, mRNA vaccines, AI-driven decision support, and wearable health tech are expected to revolutionize prevention, diagnosis, and treatment.

The market will also see a shift toward biosimilars, improving drug affordability and access. From 2020 to 2030, the global breast cancer market has grown rapidly, shaped by innovation, awareness, and policy initiatives. However, significant work remains to ensure that this progress is inclusive and sustainable.